The US Food and Drug Administration (FDA) has approved United States-based Sage Therapeutics' Zulresso (brexanolone) injection intended for the treatment of postpartum depression (PPD) in adult women, it was reported yesterday.
The approval was based on data from three multicenter, randomized, double-blind, parallel-group and placebo-controlled trials designed to assess the safety and effectiveness of Zulresso in women with moderate and severe PPD aged between 18 and 45 years.
The product is claimed to be the first and only medicine to have secured approval to treat PPD, which is the most common medical complication of childbirth. It is an allosteric modulator of both synaptic and extrasynaptic GABAA receptors.
The firm is planning to introduce the product in late June after scheduling by the US Drug Enforcement Administration, which is expected to take place within 90 days. It has also received PRIority Medicines (PRIME) designation for Zulresso from the European Medicines Agency (EMA).
FDA grants priority review to Takeda's zasocitinib application for plaque psoriasis
Armata Pharmaceuticals announces receipt of FDA Breakthrough Therapy Designation for AP-SA02
GSK reports positive Jideytro data supporting potential first-line lung cancer use
Eloxx Pharmaceuticals commences Phase 2b study of exaluren
Meant Health announces expansion of telehealth access for FDA-approved GLP-1 prescriptions
US FDA grants orphan drug designation for Lundbeck's asedebart
Renova Pharmaceuticals launches first three US generic products
FDA grants Priority Review to Genentech's Enspryng for MOGAD
CordenPharma increases aseptic fill-finish capacity
Biophytis expands BIO101 obesity study to assess weight regain
THX Pharma secures European patent for Batten-1 in juvenile Batten disease
Etcamah–CDK4/6 inhibitor combination approved in US for ESR1-mutated HR-positive breast cancer
Guardant Health wins FDA approval for Guardant360 CDx in advanced breast cancer